Makutiro Masavuli
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Makutiro is a postdoctoral researcher currently working in the Viral Immunology Group developing safe and effective vaccines against Hepatitis C (HCV), human immunodeficiency virus (HIV), Zika virus and more recently against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
-
Appointments
Date Position Institution name 2019 - ongoing Postdoctoral Researcher The University of Adelaide -
Language Competencies
Language Competency English Can read, write, speak, understand spoken and peer review French Can read, write, speak, understand spoken and peer review Swahili Can read, write, speak, understand spoken and peer review -
Education
Date Institution name Country Title 2018 University of Adelaide, Adelaide Australia PhD -
Research Interests
-
Journals
Year Citation 2023 Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., . . . Lynn, D. J. (2023). A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.. Cell Rep Med, 4(3), 1-26.
Scopus21 WoS1 Europe PMC132023 Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624.
Scopus2 Europe PMC32023 Wijesundara, D. K., Yeow, A., McMillan, C. L. D., Choo, J. J. Y., Todorovic, A., Mekonnen, Z. A., . . . Muller, D. A. (2023). Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine. Molecular Therapy Nucleic Acids, 34, 102056-1-102056-10.
Scopus12022 Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Yeow, A. E. L., . . . Lynn, D. J. (2022). Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Medicine, 20(1), 26-1-26-23.
Scopus169 WoS91 Europe PMC1302022 Perkins, G. B., Tunbridge, M., Salehi, T., Chai, C. S., Kireta, S., Johnston, J., . . . Coates, P. T. (2022). Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney International, 101(5), 1077-1080.
Scopus8 WoS5 Europe PMC62022 Garcia-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk., B. (2022). SARS-CoV-2 Omicron variant escapes neutralising antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.. Cell Reports Medicine, 3(6), 23 pages.
Scopus25 WoS15 Europe PMC232022 Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., . . . Lynn, D. J. (2022). A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses.
2021 Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Lip Yeow, A. E., . . . Lynn, D. J. (2021). Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
2021 Garcia-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk, B. (2021). COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection.
2020 Gummow, J., Masavuli, M., Mekonnen, Z. A., Li, Y., Wijesundara, D. K., Shrestha, A. C., . . . Grubor-Bauk, B. (2020). Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus. Vaccines, 8(1), 1-15.
Scopus7 WoS4 Europe PMC52020 Mekonnen, Z. A., Masavuli, M. G., Yu, W., Gummow, J., Whelan, D. M., Al-Delfi, Z., . . . Grubor-Bauk, B. (2020). Enhanced T cell responses induced by a necrotic dendritic cell vaccine, expressing HCV NS3. Front Microbiol, 11, 1-13.
Scopus6 WoS3 Europe PMC32019 Mekonnen, Z. A., Grubor-Bauk, B., Masavuli, M. G., Shrestha, A. C., Ranasinghe, C., Bull, R. A., . . . Wijesundara, D. K. (2019). Toward DNA-based T-cell mediated vaccines to target HIV-1 and hepatitis C virus: approaches to elicit localized immunity for protection. Frontiers in Cellular and Infection Microbiology, 9(APR), 1-8.
Scopus10 WoS7 Europe PMC42019 Shrestha, A. C., Wijesundara, D. K., Masavuli, M. G., Mekonnen, Z. A., Gowans, E. J., & Grubor-Bauk, B. (2019). Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines, 7(2), 14 pages.
Scopus11 WoS11 Europe PMC72019 Masavuli, M. G., Wijesundara, D. K., Underwood, A., Christiansen, D., Earnest-Silveira, L., Bull, R., . . . Grubor-Bauk, B. (2019). A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice. Frontiers in immunology, 10(MAY), 1-19.
Scopus31 WoS24 Europe PMC232019 Mekonnen, Z. A., Grubor-Bauk, B., English, K., Leung, P., Masavuli, M. G., Shrestha, A. C., . . . Wijesundara, D. K. (2019). Single-dose vaccination with a hepatotropic adeno-associated virus efficiently localizes T cell immunity in the liver with the potential to confer rapid protection against Hepatitis C virus. Journal of Virology, 93(19), e00202-19-1-e00202-19-19.
Scopus12 WoS8 Europe PMC112019 Grubor-Bauk, B., Wijesundara, D. K., Masavuli, M., Abbink, P., Peterson, R. L., Prow, N. A., . . . Gowans, E. J. (2019). NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice.. Sci Adv, 5(12), eaax2388.
Scopus54 WoS36 Europe PMC372017 Masavuli, M., Wijesundara, D., Torresi, J., Gowans, E., & Grubor-Bauk, B. (2017). Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C. Frontiers in Microbiology, 8(DEC), 11 pages.
Scopus32 WoS19 Europe PMC20 -
Conference Items
Year Citation 2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of 12th Annual Scientific Meeting of the Australian Centre for HIV and Hepatitis Virology. 2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of Adelaide Immunology Retreat. Nuriootpa. 2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of Florey Postgraduate Research Conference. 2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Enhancing the immunogenicity of HCV vaccines by fusing E1/E2 to the IMX313P multimerization technology. Poster session presented at the meeting of 24th International Symposium on Hepatitis C Virus and Related Viruses. Hyannis, Cape Cod, Massachusetts, USA. 2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccines encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day. Adeleide, Australia. 2017 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Enhancing the immunogenicity of HCV vaccines by fusing E1/E2 to the IMX313P oligomerisation technology. Poster session presented at the meeting of 9th Australasian Virology Society Meeting. 2016 Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2016). A novel DNA-based virus-like particle (VLP) vaccine against hepatitis C.. Poster session presented at the meeting of Florey Postgraduate Research Conference. 2016 Masavuli, M. G., Wijesundara, D. W., Grubor-Bauk, B., & Gowans, E. J. (2016). A DNA-based virus-like particle (VLP) vaccine against the hepatitis C virus. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day. Adelaide. 2015 Masavuli, M. G., Grubor-Bauk, B. G., Wijesundara, D. K., & Gowans, E. J. (2015). A novel DNA-based virus-like particle (VLP) vaccine for hepatitis C virus. Poster session presented at the meeting of Florey Postgraduate Research Conference. AdelaIide. 2015 Masavuli, M. G., Wijesundara, D. K., grubor-bauk, B., & gowans, E. G. (2015). A novel DNA-based virus-like particle vaccine for hepatitis C virus. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day 2015. Adelaide. -
Theses
Year Citation 2018 Masavuli, M. G. (2018). Novel DNA Vaccine Formulations Against
Hepatitis C Virus. (PhD Thesis).2013 Masavuli, M. G. (2013). Characterisation of leukocytes from IL-5 transgenic mice during Nippostrongylus brasiliensis infection.. (Undergraduate Dissertation).
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Co-Supervisor Harnessing the potential of mRNA vaccines against Hepatitis C Virus Doctor of Philosophy Doctorate Full Time Mr John Henrik Johansson 2024 Co-Supervisor This project will develop different mouse models of Zika infection in pregnancy and evaluate the efficacy in protection of different vaccine candidates Doctor of Philosophy Doctorate Full Time Ms Deborah Pratt 2022 Co-Supervisor A Trivalent Vaccine for Clinically-Important Flaviviruses. Doctor of Philosophy Doctorate Full Time Mr Ryan Santos 2021 Co-Supervisor The development of 'next generation' DNA-based vaccine against SARS-CoV-2 Doctor of Philosophy Doctorate Full Time Miss Zahraa Nima Saeed Al-Delfi
Connect With Me
External Profiles
